NASDAQ:GRDX

Entero Therapeutics Q3 2026 Earnings Results & Report

$3.24 -0.21 (-5.94%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$3.26 +0.01 (+0.46%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Entero Therapeutics reported Q3 2026 earnings on November 16, 2026. The company reported EPS of -$0.27, while revenue was $38.11 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens

Entero Therapeutics EPS Results

Actual EPS
-$0.27
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Entero Therapeutics Revenue Results

Actual Revenue
$38.11 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Entero Therapeutics Q3 2026 Earnings FAQ

Entero Therapeutics (NASDAQ:GRDX) reported earnings of -$0.27 per share for Q3 2026. The report was announced on Monday, November 16, 2026.

Entero Therapeutics reported revenue of $38.11 thousand for Q3 2026.

Entero Therapeutics Earnings Headlines

Entero Therapeutics (NASDAQ:GRDX) Upgraded to Hold at Wall Street Zen
See More Entero Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entero Therapeutics and other key companies, straight to your email.

About Entero Therapeutics

Entero Therapeutics (NASDAQ:GRDX) is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its research has focused on therapies designed to act in the digestive tract, including candidates for celiac disease, inflammatory bowel disease and exocrine pancreatic insufficiency.

Its pipeline has included latiglutenase, an oral enzyme therapy intended to break down gluten in the gut, and adrulipase, an oral enzyme replacement candidate for people with exocrine pancreatic insufficiency. These are investigational products and are not approved treatments.

The company was formerly known as First Wave BioPharma before adopting the Entero Therapeutics name. Its work has centered on developing drug candidates rather than marketing approved medicines.

View Entero Therapeutics Profile